Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting

Journal of Clinical Investigation

Volumn 117, Issue 9, 2007, Pages 2496-2505

  Guan, Youfei ^a,b   Zhang, Yahua ^a   Wu, Jing ^b   Qi, Zhonghua ^a   Yang, Guangrui ^b   Dou, Dou ^b   Gao, Yuansheng ^b   Chen, Lihong ^b   Zhang, Xiaoyan ^b   Davis, Linda S ^a   Wei, Mingfeng ^b   Fan, Xuefeng ^a   Carmosino, Monica ^a   Hao, Chuanming ^a   Imig, John D ^c   Breyer, Richard M ^d   Breyer, Matthew D ^a,d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; E PROSTANOID RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN SYNTHASE; PROSTANOID RECEPTOR; PROTEIN KINASE N; UNCLASSIFIED DRUG;

ARTICLE; BLOOD PRESSURE; DRUG EFFECT; DRUG MECHANISM; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL;

ANGIOTENSIN II; ANIMALS; BASE SEQUENCE; BLOOD PRESSURE; DINOPROSTONE; HYPERTENSION; MALE; MICE; MICE, TRANSGENIC; PROTEIN KINASE C; RATS; RATS, INBRED SHR; RECEPTORS, PROSTAGLANDIN E;

EID: 34848921161     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI29838     Document Type: Article

References (56)

1. Kobayashi, T., and Narumiya, S. 2002. Function of prostanoid receptors: studies on knockout mice. Prostaglandins Other Lipid Mediat. 68-69:557-573.
2. Breyer, M.D., and Breyer, R.M. 2000. Prostaglandin E receptors and the kidney. Am. J. Physiol. Renal Physiol. 279:F12-F23.
3. Cheng, H.F., and Harris, R.C. 2004. Cyclooxygenases, the kidney, and hypertension. Hypertension. 43:525-530.
4. Izhar, M., Alausa, T., Folker, A., Hung, E., and Bakris, G.L. 2004. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension. 43:573-577.
5. Sowers, J.R., et al. 2005. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal antiinflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch. Intern. Med. 165:161-168.
6. Grosser, T., Fries, S., and FitzGerald, G.A. 2006. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 116:4-15. doi:10.1172/JCI27291.
7. Gurwitz, J.H., et al. 1994. Initiation of antihypertensive treatment during nonsteroidal anti- inflammatory drug therapy. JAMA. 272:781-786.
8. Qi, Z., et al. 2002. Opposite ef fects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J. Clin. Invest. 110:61-69. doi:10.1172/JCI200214752.
9. Breyer, M.D., and Breyer, R.M. 2001. G protein-coupled prostanoid receptors and the kidney. Annu. Rev. Physiol. 63:579-605.
10. Qi, Z., Cai, H., Morrow, J.D., and Breyer, M.D. 2006. Differentiation of cyclooxygenase 1- and 2-derived prostanoids in mouse kidney and aorta. Hypertension. 48:323-328.
11. Narumiya, S., Sugimoto, Y., and Ushikubi, F. 1999. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79:1193-1226.
12. Tsuboi, K., Sugimoto, Y., and Ichikawa, A. 2002. Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat. 68-69:535-556.
13. Kennedy, C.R., et al. 1999. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat. Med. 5:217-220.
14. Nadler, J., Zipser, R.D., Coleman, R., and Horton, R. 1983. Stimulation of renal prostaglandins by pressor hormones in man: comparison of prostaglandin E2 and prostacyclin (6 keto prostaglandin F1 alpha). J. Clin. Endocrinol. Metab. 56:1260-1265.
15. Siragy, H.M., Senbonmatsu, T., Ichiki, T., Inagami, T., and Carey, R.M. 1999. Increased renal vasodilator prostanoids prevent hypertension in mice lacking the angiotensin subtype-2 receptor. J. Clin. Invest. 104:181-188.
16. Takeuchi, K., et al. 1999. Prostaglandin E receptor subtypes involved in stimulation of gastroduodenal bicarbonate secretion in rats and mice. J. Physiol. Pharmacol. 50:155-167.
17. Hallinan, E., Stapelfeld, A., Savage, M., and Reichman, M. 1994. 8-chlorodibenz[B,F][1, 4]oxazepine-10(11H)-carboxylic acid, 2-[3-2- (furanylmethyl)thio]-1-oxopropyl]hydrazide (SC51322): a potent PGE2 antagonist and analgesic. Bioorg. Med. Chem. Lett. 4:509-514.
18. Hallinan, E.A., et al. 1993. N-substituted dibenzoxazepines as analgesic PGE2 antagonists. J. Med. Chem. 36:3293-3299.
19. Stock, J.L., et al. 2001. The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure. J. Clin. Invest. 107:325-331.
20. Batshake, B., and Sundelin, J. 1996. The mouse genes for the EP1 prostanoid receptor and the PKN protein kinase overlap. Biochem. Biophys. Res. Commun. 227:70-76.
21. Mukai, H. 2003. The structure and function of PKN, a protein kinase having a catalytic domain homologous to that of PKC. J. Biochem. (Tokyo). 133:17-27.
22. Pravenec, M., et al. 1999. Genetics of Cd36 and the clustering of multiple cardiovascular risk factors in spontaneous hypertension. J. Clin. Invest. 103:1651-1657.
23. Hefferan, M.P., Carter, P., Haley, M., and Loomis, C.W. 2003. Spinal nerve injury activates prostaglandin synthesis in the spinal cord that contributes to early maintenance of tactile allodynia. Pain. 101:139-147.
24. Ishibashi, R., et al. 1999. Roles of prostaglandin E receptors in mesangial cells under high-glucose conditions. Kidney Int. 56:589-600.
25. Hasty, P., Ramirez-Solis, R., Krumlauf, R., and Bradley, A. 1991. Introduction of a subtle mutation into the Hox-2.6 locus in embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 50:243-246.
26. Guan, Y., et al. 1998. Prostaglandin E2 inhibits renal collecting duct Na+ absorption by activating the EP1 receptor. J. Clin. Invest. 102:194-201.
27. Katoh, H., Watabe, A., Sugimoto, Y., Ichikawa, A., and Negishi, M. 1995. Characterization of the signal transduction of prostaglandin E receptor EP1 subtype in cDNA-transfected Chinese hamster ovary cells. Biochim. Biophys. Acta. 1244:41-48.
28. Watabe, A., et al. 1993. Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E receptor. J. Biol. Chem. 268:20175- 20178.
29. Zhang, Y., et al. 2000. Characterization of murine vasopressor and vasodepressor prostaglandin E(2) receptors. Hypertension. 35:1129-1134.
30. Audoly, L.P., et al. 1999. Identification of specific EP receptors responsible for the hemodynamic effects of PGE2. Am. J. Physiol. 277:H924-H930.
31. Zhang, Y., et al. 2000. Characterization of murine vasopressor and vasodepressor prostaglandin E2 receptors. Hypertension. 35:1129-1134.
32. Durocher, Y., et al. 2000. A reporter gene assay for high-throughput screening of G-protein-coupled receptors stably or transiently expressed in HEK293 EBNA cells grown in suspension culture. Anal. Biochem. 284:316-326.
33. Qi, Z., et al. 2002. Opposite ef fects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J. Clin. Invest. 110:61-69. doi:10.1172/JCI200214752.
34. Chatziantoniou, C., and Arendshorst, W.J. 1992. Impaired ability of prostaglandins to buffer renal vasoconstriction in genetically hypertensive rats. Am. J. Physiol. 263:F573-F580.
35. Sugimoto, Y., Narumiya, S., and Ichikawa, A. 2000. Distribution and function of prostanoid receptors: studies from knockout mice. Prog. Lipid Res. 39:289-314.
36. Breyer, M.D., Davis, L., Jacobson, H.R., and Breyer, R.M. 1996. Differential localization of prostaglandin E receptor subtypes in human kidney. Am. J. Physiol. 270:F912-F918.
37. Ahn, D., et al. 2004. Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J. Clin. Invest. 114:504-511. doi:10.1172/JCI200421064.
38. Hébert, R., Jacobson, H., and Breyer, M. 1990. PGE2 inhibits AVP induced water flow in cortical collecting ducts by protein kinase C activation. Am. J. Physiol. 259:F318-F325.
39. Yang, T., et al. 1998. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am. J. Physiol. 274:F481-F489.
40. Batshake, B., Nilsson, C., and Sundelin, J. 1995. Molecular characterization of the mouse prostanoid EP1 receptor gene. Eur. J. Biochem. 231:809-814.
41. Boie, Y., et al. 1997. Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur. J. Pharmacol. 340:227-241.
42. Kiriyama, M., et al. 1997. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 122:217-224.
43. Rao, R., et al. 2007. Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo. J. Biol. Chem. 282:16959-16968.
44. Southall, M.D., and Vasko, M.R. 2001. Prostaglandin receptor subtypes, EP3C and EP4, mediate the prostaglandin E2-induced cAMP production and sensitization of sensory neurons. J. Biol. Chem. 276:16083-16091.
45. Kubo, S., et al. 2004. E-prostanoid (EP)2/EP4 receptor-dependent maturation of human monocyte-derived dendritic cells and induction of helper T2 polarization. J. Pharmacol. Exp. Ther. 309:1213-1220.
46. Ohnaka, K., Numaguchi, K., Yamakawa, T., and Inagami, T. 2000. Induction of cyclooxygenase-2 by angiotensin II in cultured rat vascular smooth muscle cells. Hypertension. 35:68-75.
47. Purdy, K.E., and Arendshorst, W.J. 1999. Prostaglandins buffer ANG II-mediated increases in cytosolic calcium in preglomerular VSMC. Am. J. Physiol. 277:F850-F858.
48. Satoh, H., and Satoh, S. 1984. Prostaglandin E2 and I2 production in isolated dog renal arteries in the absence or presence of vascular endothelial cells. Biochem. Biophys. Res. Commun. 118:873-876.
49. Francois, H., Athirakul, K., Mao, L., Rockman, H., and Coffman, T.M. 2004. Role for thromboxane receptors in angiotensin-II-induced hypertension. Hypertension. 43:364-369.
50. Crowley, S.D., et al. 2005. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J. Clin. Invest. 115:1092-1099. doi:10.1172/JCI200523378.
51. Negus, P., Tannen, R.L., and Dunn, M.J. 1976. Indomethacin potentiates the vasoconstrictor actions of angiotensin II in normal man. Prostaglandins. 12:175-180.
52. MacMillan, L.B., Hein, L., Smith, M.S., Piascik, M.T., and Limbird, L.E. 1996. Central hypotensive effects of the alpha2a-adrenergic receptor subtype. Science. 273:801-803.
53. Schyvens, C.G., Mangos, G.J., Zhang, Y., McKenzie, K.U., and Whitworth, J.A. 2001. Telemetric monitoring of adrenocorticotrophin-induced hypertension in mice. Clin. Exp. Pharmacol. Physiol. 28:758-760.
54. Imig, J.D., Breyer, M.D., and Breyer, R.M. 2002. Contribution of prostaglandin EP(2) receptors to renal microvascular reactivity in mice. Am. J. Physiol. Renal Physiol. 283:F415-F422.
55. Wang, X., Tong, M., Chinta, S., Raj, J.U., and Gao, Y. 2006. Hypoxia-induced reactive oxygen species downregulate ETB receptor-mediated contraction of rat pulmonary arteries. Am. J. Physiol. Lung Cell Mol. Physiol. 290:L570-L578.
56. Breyer, M.D. 1991. Feedback inhibition of cyclic adenosine monophosphate-stimulated Na+ transport in the rabbit cortical collecting duct via Na(+)-dependent basolateral Ca++ entry. J. Clin. Invest. 88:1502-1510.